ASH 2024 | MRD negativity in the CARTITUDE-4 trial of cilta-cel vs SoC in R/R multiple myeloma

So at ASH 2024 this year, the investigator on the CARTITUDE-4 clinical trial will be presenting data on MRD results. And so this is a randomized controlled clinical trial for which Cilta-cel or Carvykti, the BCMA targeting CAR-T was approved in earlier line of therapy for patients with multiple myeloma. So we already saw in this randomized control study that a single dose treatment of cilta-cel yielded better PFS and in a very recent report as well now a statistically significant improvement in OS as well compared to standard of care triplet regimens. Not surprisingly, what we know is across all therapy modalities for myeloma, if patients are able to maintain, first of all reach MRD negative response, which is an even deeper response than a complete remission, and particularly maintaining it for a year or longer, those patients generally can do even better. And indeed, that is what we saw on this study, that patients on the cilta-cel arm had a much higher MRD negative rate. In fact, up to six times compared to standard of care arm. And so for those patients on the cilta-cel arm who reached and maintained that MRD negative rate, their 30 months PFS and OS rates are very, very high. You know, high 90s, almost close to 100%. So this speaks to that cilta-cel can have a very deep response that translates to sustained durability of remission. And for patients who are able to reach these deep responses, they will have PFS that is going to, you know, eventually translate to a product with a much longer than the median PFS.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.